GLPwatch
Papers (9189)
Page 138 of 154, ranked by citation count.
- The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation.
- Tirzepatide mitigates thoracic aortic aneurysm and dissection by alleviating the loss of the contractile phenotype in vascular smooth muscle cells and reducing vascular inflammation.
- Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study.
- The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.
- Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.
- Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide.
- Addressing the obesity challenge in plastic surgery - the role of liraglutide.
- Glucagon-like peptide-1 analog, liraglutide, alters blood-testis barrier permeability in juvenile healthy rats.
- Efficacy of Simplifying Complex Insulin Regimen on Glycometabolic Parameters and Target Organ Damage in Type 2 Diabetes: A Retrospective Cohort Study.
- Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.
- Antidiabetic drugs in Parkinson's disease: a comprehensive meta-analysis on efficacy and safety with trial sequential analysis and GRADE evaluation.
- [ANMCO Statement: semaglutide in cardio-nephro-metabolic disorders].
- Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.
- Once-Weekly Mazdutide in Obesity or Overweight.
- Once-Weekly Mazdutide in Obesity or Overweight. Reply.
- Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney Disease.
- Nutritional Challenges in Post-Massive Weight Loss Body Contouring: Guidance for Plastic Surgeons on GLP-1 Agonists and Sleeve Gastrectomy.
- Ethical Considerations in the Use of Weight Loss Medications.
- LiCl-driven direct synthesis of mono-protected esters from long-chain dicarboxylic fatty acids.
- The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.
- Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction.
- Glucagon-Like Peptide-1 Receptor Agonists: A Novel Indication for Substance Use Disorders?
- GLP-1 Receptor Agonist-Associated Slimmer's Palsy: Implications for the Peripheral Nerve Surgeon.
- Pharmacological Management of Diabesity: Current and Emerging Therapies.
- Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.
- Predicting Weight Outcomes From Obesity Medications in a Paediatric Population.
- Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.
- Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review.
- Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study.
- A Bibliometric Analysis Review of the Top 50 Most Cited Articles on Incretin-Based Therapy for Weight Reduction and Diabetes Management.
- Glucagon-like peptide-1 receptor agonist use and clinical outcomes after posterior cervical spinal fusion for degenerative pathologies: A large cohort retrospective analysis.
- TikTokfluence: The rise of GLP-1 receptor agonists in the age of social media health trends.
- Endocrinology: What You May Have Missed in 2025.
- Methodological and statistical inconsistencies compromise the efficacy and safety analyses of orforglipron.
- Iixisenatide. Wait for conclusive results on complications of diabetes.
- Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF.
- Summary for Patients: Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide.
- A Fluorescent Probe-Based Platform for Precise Pharmaceutical Analysis and Quality Assessment of Tirzepatide.
- Any expectations from the more powerful dulaglutide?
- Diabetes News.
- A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland.
- Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China.
- Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular-kidney-metabolic stage progression: a real-world cohort study.
- Short-Term Associations Between Fat-Free Mass Preservation and Glycaemic Markers During Tirzepatide Therapy: A Secondary Exploratory Analysis.
- Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study.
- Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus.
- Insulin degludec, Lixisenatide, and Patiromer sorbitex calcium.
- Tirzepatide - A major breakthrough in the fight against obesity.
- Tirzepatide: A promising treatment for obesity?
- Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.
- Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice.
- Patient-Reported Outcomes in People With Type 2 Diabetes Escalating Dulaglutide or Switching From Dulaglutide to Tirzepatide.
- Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study.
- Assessing the Safety of Semaglutide and Tirzepatide in Black and Asian Populations: A Narrative Review.
- Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
- Weight "regain" in obesity shifts responsibility from biology to personal inadequacy.
- Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy.
- [Basal insulin glargine-lixisenatide fixed ratio combination (Suliqua®)].
- In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.
- Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes.